FDA — authorised 6 August 2007
- Application: NDA022128
- Marketing authorisation holder: VIIV HLTHCARE
- Local brand name: SELZENTRY
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 optimized background therapy in United States
FDA authorised optimized background therapy on 6 August 2007
Marketing authorisations
FDA — authorised 4 November 2016
- Application: NDA208984
- Marketing authorisation holder: VIIV HLTHCARE
- Local brand name: SELZENTRY
- Indication: SOLUTION — ORAL
- Status: approved
Frequently asked questions
Is optimized background therapy approved in United States?
Yes. FDA authorised it on 6 August 2007; FDA authorised it on 4 November 2016.
Who is the marketing authorisation holder for optimized background therapy in United States?
VIIV HLTHCARE holds the US marketing authorisation.